Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pralurbactam
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Pralurbactam (formerly known as FL058) is a novel diazabicyclooctane (DBO) beta-lactamase inhibitor developed by Qilu Pharmaceutical. It is designed to restore the activity of carbapenems, such as meropenem, against multidrug-resistant Gram-negative bacteria, particularly those producing Ambler Class A (including KPC), Class C (AmpC), and certain Class D (such as OXA-48) serine beta-lactamases. Pralurbactam works by covalently and reversibly binding to the active site of these enzymes, preventing them from hydrolyzing co-administered beta-lactam antibiotics. It is currently being evaluated in clinical trials as a fixed-dose combination with meropenem (Meropenem-pralurbactam) for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI) and acute pyelonephritis.
- Other names
- pralurbactamum
02
Targets
Class A BL (Class A beta-lactamase)OXA (Class D beta-lactamase)AmpC (AmpC beta-lactamase)
Beyond the preview
Go deeper on pralurbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pralurbactam.